The UK has the science, policy ambition and institutions to become a global life sciences leader. Here, the authors discuss why this moment feels different. Together, they explain why health is an investment, how innovation can support NHS reform and what practical action is needed to deliver its full value today.
After decades working across UK life sciences, they have both seen no shortage of strategies, reforms and declarations of intent. Amy has spent around 25 years in pharmaceutical commercial leadership, working across areas including immunology, dermatology, gastroenterology and pulmonary arterial hypertension. Nina’s career has taken her from the civil service to NICE, NHS England and the Office for Life Sciences, helping to create some of the systems through which innovative medicines are evaluated and made available.
Both have heard the UK’s ambition to become a global life sciences leader before. Yet both believe this moment feels different.
Read the article in full here.